Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

NCT01683994 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

NIH

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Cabozantinib
DRUG: Docetaxel
DRUG: Prednisone

Sponsor

National Cancer Institute (NCI)